Home Cart Sign in  
Chemical Structure| 1445987-21-2 Chemical Structure| 1445987-21-2

Structure of Ivarmacitinib
CAS No.: 1445987-21-2

Chemical Structure| 1445987-21-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ivarmacitinib (SHR0302) is an effective and orally active JAK inhibitor, showing a selectivity for JAK1 that is 10 times higher than JAK2, 77 times higher than JAK3, and 420 times higher than Tyk2. It inhibits JAK1-STAT3 phosphorylation and induces apoptosis in hepatic stellate cells, with antiproliferative and anti-inflammatory effects.

Synonyms: SHR0302

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ivarmacitinib

CAS No. :1445987-21-2
Formula : C18H22N8O2S
M.W : 414.48
SMILES Code : CN([C@H]1C[C@@]2([H])[C@@](CN(C2)C(NC3=NC(OC)=NS3)=O)([H])C1)C4=C5C(NC=C5)=NC=N4
Synonyms :
SHR0302
MDL No. :MFCD32701909
InChI Key :DNBCBAXDWNDRNO-FOSCPWQOSA-N
Pubchem ID :71622431

Safety of Ivarmacitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Ivarmacitinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04346316 Alopecia Areata PHASE2 COMPLETED 2021-06-29 Quest Dermatology Research, No... More >>rthridge, California, 91324, United States|Moore Clinical Research, Brandon, Florida, 33511, United States|Dawes Fretzin Clinical Research, Indianapolis, Indiana, 46250, United States|Skin Search of Rochester, Inc, Rochester, New York, 14623, United States|Dermatologists of Southwest Ohio, Mason, Ohio, 45040, United States|The Skin Wellness Center, Knoxville, Tennessee, 37922, United States|Progressive Clinical Research, San Antonio, Texas, 78213, United States|St George Dermatology and Skin Cancer Centre, Kogarah, New South Wales, 2217, Australia|Novatrials, Kogarah, New South Wales, 2289, Australia|Veracity Clinical Research, Woolloongabba, Queensland, 4102, Australia|Skin Health Institute, Carlton, Victoria, 3053, Australia|Sinclair Dermatology, East Melbourne, Victoria, 3002, Australia|Sinclair Dermatology, Melbourne, Victoria, 3002, Australia|China-Japan Friendship Hospital, Beijing, Beijing, 100029, China|Peking University First Hospital, Beijing, Beijing, 100034, China|Peking University People's Hospital, Beijing, Beijing, 100044, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, 100050, China|Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, 100730, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Chongqing Traditional Chinese medicine Hospital, Chongqing, Chongqing, 400011, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, 400016, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510030, China|The Dermatology Hospital of Nanfang Medical University, Guangzhou, Guangdong, China|The Dermatology Hospital of Nanfang Medical University, Guangzhou, Guangzhou, China|Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China|Jiangsu Province People's Hospital, Nanjin, Jiangsu, 210029, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China|Shanghai Skin Disease Hospital, Shanghai, Shanghai, 200071, China|Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, Tianjin, 300120, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China|SIR RUN RUN Shaw Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310020, China Less <<
NCT05856058 Graft-versus-host Disease PHASE1 COMPLETED 2023-10-09 Beijing Hospital, Beijing, Bei... More >>jing, 100005, China Less <<
NCT02892370 Rheumatoid Arthritis PHASE1 UNKNOWN 2025-10-16 Shanghai Xuhui Central Hospita... More >>l, Shanghai, Shanghai, 200030, China Less <<
NCT05900089 Peripheral T Cell Lymphoma PHASE1 NOT_YET_RECRUITING 2026-06-01 Henan cancer hospital, Zhengzh... More >>ou, Henan, China Less <<
NCT04293029 Hepatic Impairment PHASE1 COMPLETED 2020-12-30 The First Affiliated Hospital ... More >>of Jilin University, Changchun, Jilin, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.06mL

2.41mL

1.21mL

24.13mL

4.83mL

2.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories